Novartis seeks next generation of malaria drugs
Last Updated on Friday, 2 June 2006 06:19 Written by admin Friday, 2 June 2006 06:19
Determined to eradicate a disease that takes the lives of more than one million people worldwide each year, Novartis has announced it will participate in a new public-private partnership which aims to discover more potent drugs to combat malaria.
The Novartis Institute for Tropical Diseases (NITD) will focus on the development of a one-dose cure for Plasmodium falciparum, the most dangerous form of malaria, and a curative modality for Plasmodium vivax, the most frequent and widely distributed cause of malaria.
This entry was posted on Friday, June 2nd, 2006 at 6:19 pm and is filed under Medicinal Chemistry.
You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory